Swedish health-tech company Elekta to advance cancer treatments with €100 million EIB loan
Summary
Elekta secured up to €100 million from the European Investment Bank to support research and development in cancer and neurological treatment technologies. The company will use the financing to advance radiotherapy, radiosurgery, brachytherapy, and the software that plans and delivers these therapies. Elekta plans to invest about €200 million in its research program between 2026 and 2029, with most work taking place in Sweden and the Netherlands. The financing supports efforts to improve treatment accuracy, efficiency, and patient outcomes as demand for cancer care rises.
Funding
Amount
$108.0M
Total raised
Date
August 31, 2026
Announcement date
Investors
European Investment Bank
Lead investors
Company
elekta.com
Funded company
AskAI Classifications
Sectors
HealthTech
General Healthcare software
Medical Imaging Software
Functions
No functions detected
Linked Companies
Elekta
$1M to $5M